|
|
| | Gamitrinib TPP hexafluorophosphate Basic information |
| | Gamitrinib TPP hexafluorophosphate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 50 mg/mL (48.26 mM) | | form | Solid | | color | Pale purple to purple |
| | Gamitrinib TPP hexafluorophosphate Usage And Synthesis |
| Uses | Gamitrinib TPP hexafluorophosphate is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity. | | in vivo | Whether the combination of TRAIL plus Gamitrinib TPP (GamitrinibTPP, G-TPP) has activity against glioblastoma in vivo is studied. Luciferase-expressing U87 glioblastoma cells implanted in the right cerebral striatum of immunocompromised mice give rise to rapidly growing tumors by bioluminescence imaging, and treatment of these mice with vehicle, stereotactic delivery of TRAIL, or systemic administration of suboptimal concentrations of Gamitrinib TPP does not affect tumor growth in vivo. Similarly, systemic monotherapy with Gamitrinib TPP at concentrations (20 mg/kg as daily i.p. injections) that inhibit subcutaneous xenograft tumor growth in mice has no effect on orthotopic glioblastoma growth. In contrast, 2 cycles of intracranial TRAIL combined with systemic Gamitrinib TPP suppresses the growth of established glioblastomas, with no significant animal weight loss throughout treatment[1]. | | IC 50 | HSP90 | | References | [1] Markus D. Siegelin, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011 Apr 1; 121(4): 1349–1360. DOI:10.1172/JCI44855 |
| | Gamitrinib TPP hexafluorophosphate Preparation Products And Raw materials |
|